Myovant's Relugolix Shows Promising Profile For Endometriosis Pain

The first Phase III trial testing relugolix combination therapy in endometriosis pain showed efficacy with minimal bone mineral density loss, an issue with AbbVie's rival drug Orilissa. An US NDA was also filed in prostate cancer.

A chess king last stand as a true winner.Money game concept. Copy space.
Myovant's Orilissa appears to have a competitive profile • Source: Shutterstock

Myovant Sciences Ltd.'s relugolix appears well positioned to compete against AbbVie Inc.'s Orilissa (elagolix), which it will trail to the market, for endometriosis pain. Relugolix demonstrated significant reductions in endometriosis pain in the first of two Phase III studies to read out, and with minimal bone mineral density (BMD) loss, a safety issue associated with Orilissa.

Myovant announced positive data from the first Phase III trial in endometriosis pain on 22 April, one day after the...

More from Clinical Trials

More from R&D